The @-mg dose showed an effect on exploratory end points including a @ % decrease in celiac disease patient-reported outcome symptomatic days ( P = @ ) , a @ % increase in improved symptom days ( P = @ ) , a @ % or more reduction from baseline of the weekly average abdominal pain score for @ or more of @ weeks of treatment ( P = @ ) , and a decrease in the nongastrointestinal symptoms of headache and tiredness ( P = @ ) .